Department of Orthopedics, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Department of Biophysics, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Bone. 2020 Sep;138:115507. doi: 10.1016/j.bone.2020.115507. Epub 2020 Jun 28.
To identify epigenetic and transcriptional factors controlling osteoclastogenesis (OCG), that have been shown to play a role in the pathogenesis of skeletal diseases.
A systematic review was conducted in accordance with the PRISMA guidelines. The PubMed and EMBASE databases were searched up to 30th April 2020; references of included articles and pertinent review articles were also screened to identify eligible studies. Studies were included if they described epigenetic and/or transcriptional regulation of OCG in a specific skeletal disorder, and quantified alterations in OCG by any well-described experimental method. Risk of bias was assessed by a previously described modification of the CAMARADES tool.
The combined searches yielded 2265 records. Out of these, 24 studies investigating 12 different skeletal disorders were included in the review. Osteoporosis, followed by osteopetrosis, was the most commonly evaluated disorder. A total of 22 different epigenetic and transcriptional regulators of OCG were identified; key epigenetic regulators included DNA methylation, histone methylation, histone acetylation, miRNAs and lncRNAs. In majority of the disorders, dysregulated OCG was noted to occur at the stage of formation of committed osteoclast from preosteoclast. Dysregulation the stage of formation of the preosteoclast from late monocyte was noted in rheumatoid arthritis and fracture, whereas dysregulation at stage of formation of late monocyte from early monocyte was noted in osteopetrosis and spondyloarthritis. Quality assessment revealed a high risk of bias in domains pertaining to randomization, allocation concealment, blinding of outcome assessors and determination of sample size.
A variety of epigenetic and transcriptional factors can result in dysregulated osteoclastogenesis in different skeletal disorders. Dysregulation can occur at any stage; however, the formation of committed osteoclasts from preosteoclasts is the most common target. Although the published literature on this subject seems promising, the overall strength of evidence is limited by the small number of studies evaluating individual skeletal disorders, and also by deficiencies in key aspects of study design.
确定控制破骨细胞生成(OCG)的表观遗传和转录因子,这些因子已被证明在骨骼疾病的发病机制中起作用。
按照 PRISMA 指南进行系统综述。检索 PubMed 和 EMBASE 数据库,截至 2020 年 4 月 30 日;还筛选了纳入文章的参考文献和相关综述文章,以确定符合条件的研究。如果研究描述了特定骨骼疾病中 OCG 的表观遗传和/或转录调控,并通过任何描述良好的实验方法定量改变了 OCG,则将其纳入研究。使用先前描述的 CAMARADES 工具的修改版评估偏倚风险。
联合检索共产生 2265 条记录。在这些记录中,有 24 项研究调查了 12 种不同的骨骼疾病,被纳入综述。骨质疏松症,其次是骨质增生症,是最常评估的疾病。总共确定了 22 种不同的 OCG 表观遗传和转录调节因子;关键的表观遗传调节因子包括 DNA 甲基化、组蛋白甲基化、组蛋白乙酰化、miRNA 和 lncRNA。在大多数疾病中,从前破骨细胞到破骨细胞的形成阶段观察到破骨细胞失调。在类风湿关节炎和骨折中,从晚期单核细胞到前破骨细胞的形成阶段观察到调节失调,而在骨质增生症和脊柱关节炎中,从早期单核细胞到晚期单核细胞的形成阶段观察到调节失调。质量评估显示,在随机化、分配隐藏、结果评估者盲法和样本量确定方面存在高偏倚风险。
多种表观遗传和转录因子可导致不同骨骼疾病中破骨细胞生成失调。失调可能发生在任何阶段;然而,从前破骨细胞到破骨细胞的形成是最常见的靶点。尽管关于这个主题的已发表文献似乎很有希望,但由于评估个别骨骼疾病的研究数量较少,以及研究设计的关键方面存在缺陷,证据的整体强度有限。